2036
Trademark domain | |
name | is free? |
---|---|
2036.com |
The "2036" trademark, serial number 78881284 , was filed on 11th of May 2006 with a mark drawing code of 4000 and its transaction date is 78881284. The attorney assigned is John Clarke Holman, attorney docket number T35924US0. Since 31st of December 2009, the document can be found in the L20 law office in the publication and issue section. The employee responsible is BAKER, JORDAN A and the date it was published for opposition on 07/31/2007. The status of this trademark was checked last on 04/24/2008.
Other trademarks by this attorney include , GREYWACKE , PHARMATEX . The corresponded responsible for this trademark is JOHN CLARKE HOLMAN, located at JACOBSON HOLMAN PLLC, 400 7TH ST NW, WASHINGTON, DC 20004-2237.The state or country where the trademark was organized is by Kindway International Limited. The legal entity type behing it is a Other (Indicates Entity-Statement should appear)., located at 77 Des Voeux Road Central, Hong Kong, zip .
GOODS AND/OR SERVICES | |
International Class - 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. | |
---|---|
U.S. Class | 052 - Detergents and Soaps |
Class Status | 6 - Active |
Status Date | 05/17/2006 |
Primary Code | 005 |
Goods codes | |
GS0051 | Pharmaceutical, veterinary, and sanitary preparations, all used for the treatment of infectious diseases, namely, respiratory infections, eye infections, for the treatment of inflammatory diseases, namely, inflammatory bowel diseases, inflammatory connective tissue diseases, for the treatment of psychiatric diseases, namely, mood disorders, anxiety disorders, cognitive disorders, for the treatment of neurological disorders, namely, brain injury, spinal cord injury, seizure disorders, for the treatment of the central nervous system, namely, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, for the treatment of immunologic diseases, namely, autoimmune diseases, immunologic deficiency syndromes, for use in dermatology, namely, dermatitis, skin pigmentation diseases, sexually transmitted diseases, for the treatment of genitourinary diseases, namely, urological diseases, infertility, sexually transmitted diseases, inflammatory pelvic diseases, for the treatment of the musculo-skeletal system, namely, connective tissue diseases, bone diseases, spinal diseases, back pain, fractures, sprains, cartilage injuries, for use in ophthalmology, for the treatment of dental and oral diseases, for use in gastroenterology; for the treatment of the respiratory system, for use in ocular disorders, for the treatment of cardiovascular diseases, acne medication, allergy medication, antacids, anthelmintics, anti-arrhythmics, antibiotic creams and ointments, antibiotics, anticoagulants, anticonvulsants, antidepressants, antiemetics, antiflatulants, antihistamines, antihypertensives anti-infectives, anti-inflammatories, antiparasites, antivirals, burn relief medications, calcium channels blockers, central nervous system depressants, central nervous system stimulants, cough treatment medication, diarrhea medication, fungal medications, gastro-intestinal pharmaceutical preparations, glaucoma agents, hydrocortisone, hypnotic agents, sedatives; dietetic substances, namely foods, adapted for medical use; vitamin supplements, mineral food supplements; herbal extracts for medical purposes; medicated extracts of plants and herbs in the form of capsules, tablets, liquid concentrate, powder, and crystals; dietetic supplements for medical use and nutritious health food supplement for medical use all made primarily of lingzhi spores, lingzhi spore lipids, yunzhi, bee glue or propolis, or cordyceps or extracts therefrom; lingzhi granules, lingzhi pills, lingzhi capsules, lingzhi tablets; and medicinal tea made primarily of lingzhi spores; Chinese herbal medicines, and Chinese patent medicines all composed of lingzhi spores, lingzhi spore lipids, yunzhi, bee glue, propolis, or cordyceps, and used for the treatment of infectious diseases, namely, respiratory infections, eye infections, for the treatment of inflammatory diseases, namely, inflammatory bowel diseases, inflammatory connective tissue diseases, for the treatment of psychiatric diseases, namely, mood disorders, anxiety disorders, cognitive disorders, for the treatment of neurological disorders, namely, brain injury, spinal cord injury, seizure disorders, for the treatment of the central nervous system, namely, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, for the treatment of immunologic diseases, namely, autoimmune diseases, immunologic deficiency syndromes, for use in dermatology, namely, dermatitis, skin pigmentation diseases, sexually transmitted diseases, for the treatment of genitourinary diseases, namely, urological diseases, infertility, sexually transmitted diseases, inflammatory pelvic diseases, for the treatment of the musculo-skeletal system, namely, connective tissue diseases, bone diseases, spinal diseases, back pain, fractures, sprains, cartilage injuries, for use in ophthalmology, for the treatment of dental and oral diseases, for use in gastroenterology, for the treatment of the respiratory system, for use in ocular disorders, for the treatment of cardiovascular diseases, acne medication, allergy medication, antacids, anthelmintics, anti-arrhythmics, antibiotic creams and ointments, antibiotics, anticoagulants, anticonvulsants, antidepressants, antiemetics, antiflatulants, antihistamines, antihypertensives anti-infectives, anti-inflammatories, antiparasites, antivirals, burn relief medications, calcium channels blockers, central nervous system depressants, central nervous system, stimulants, cough treatment medication, diarrhea medication, fungal medications, gastro-intestinal pharmaceutical preparations, glaucoma agents, hydrocortisone, hypnotic agents, sedatives |
PM0001 | TWO THOUSAND THIRTY-SIX |
PROSECUTION HISTORY | ||||
Date | Description | Type | Code | |
---|---|---|---|---|
07/11/2007 | NOTICE OF PUBLICATION | O - Outgoing Correspondence | NPUB - NOTICE OF PUBLICATION | |
06/25/2008 | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | O - Outgoing Correspondence | MAB6 - ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | |
06/25/2008 | ABANDONMENT - NO USE STATEMENT FILED | S | ABN6 - ABANDONMENT - NO USE STATEMENT FILED | |
10/23/2007 | NOA MAILED - SOU REQUIRED FROM APPLICANT | O - Outgoing Correspondence | NOAM - NOTICE OF ALLOWANCE-MAILED | |
07/31/2007 | PUBLISHED FOR OPPOSITION | A - Allowance for Publication | PUBO - PUBLISHED FOR OPPOSITION | |
05/10/2007 | LAW OFFICE PUBLICATION REVIEW COMPLETED | O - Outgoing Correspondence | PREV - LAW OFFICE PUBLICATION REVIEW COMPLETED | |
05/02/2007 | ASSIGNED TO LIE | A - Allowance for Publication | ALIE - ASSIGNED TO LIE | |
04/12/2007 | EXAMINERS AMENDMENT MAILED | O - Outgoing Correspondence | CNEA - EXAMINERS AMENDMENT MAILED | |
04/12/2007 | APPROVED FOR PUB - PRINCIPAL REGISTER | P | CNSA - APPROVED FOR PUB - PRINCIPAL REGISTER | |
04/12/2007 | EXAMINER'S AMENDMENT ENTERED | I - Incoming Correspondence | XAEC - EXAMINER'S AMENDMENT ENTERED | |
04/12/2007 | EXAMINERS AMENDMENT -WRITTEN | R - Renewal | CNEA - EXAMINERS AMENDMENT -WRITTEN | |
04/10/2007 | TEAS/EMAIL CORRESPONDENCE ENTERED | I - Incoming Correspondence | TEME - TEAS/EMAIL CORRESPONDENCE ENTERED | |
04/09/2007 | CORRESPONDENCE RECEIVED IN LAW OFFICE | I - Incoming Correspondence | CRFA - CORRESPONDENCE RECEIVED IN LAW OFFICE | |
04/09/2007 | TEAS RESPONSE TO OFFICE ACTION RECEIVED | I - Incoming Correspondence | TROA - TEAS RESPONSE TO OFFICE ACTION RECEIVED | |
10/16/2006 | NON-FINAL ACTION MAILED | F - First Action | CNRT - NON-FINAL ACTION MAILED | |
10/16/2006 | NON-FINAL ACTION WRITTEN | R - Renewal | CNRT - NON-FINAL ACTION WRITTEN | |
10/14/2006 | ASSIGNED TO EXAMINER | D - Assigned to Examiner | DOCK - ASSIGNED TO EXAMINER | |
06/26/2006 | APPLICANT AMENDMENT PRIOR TO EXAMINATION - ENTERED | O - Outgoing Correspondence | AMPX - APPLICANT AMENDMENT PRIOR TO EXAMINATION - ENTERED | |
06/26/2006 | TEAS VOLUNTARY AMENDMENT RECEIVED | I - Incoming Correspondence | PARI - TEAS PRELIMINARY AMENDMENT RECEIVED | |
05/17/2006 | NEW APPLICATION ENTERED IN TRAM | I - Incoming Correspondence | NWAP - NEW APPLICATION ENTERED IN TRAM |
Information gathered on 12/31/2009. No claim is made regarding the current trademark status. This page is not to be used as legal documentation. Always consult a licensed attorney.
This web site is not associated with, endorsed by, or sponsored by and has no official or unofficial affiliation with the trademark's owners.